Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans

Xenobiotica

Volumn 37, Issue 4, 2007, Pages 416-426

  Nakagomi Hagihara, R ^a   Nakai, D ^a   Tokui, T ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Drug drug interaction; Gemfibrozil; OAT; Pravastatin

Indexed keywords

DRUG METABOLITE; GEMFIBROZIL; GEMFIBROZIL GLUCURONIDE; GEMFIBROZIL M3; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PRAVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; KIDNEY CLEARANCE; MICHAELIS CONSTANT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; GEMFIBROZIL; HUMANS; KIDNEY; MICE; MICE, TRANSGENIC; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PRAVASTATIN;

EID: 34147133352     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250601188808     Document Type: Article

References (33)

1. Abdul-Ghaffar NU, El-Sonbaty MR. 1995. Pancreatitis and rhabdomyolysis associated with lovastatin - gemfibrozil therapy. Journal of Clinical Gastroenterology 21:340-341.
2. Asberg A. 2003. Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 63:367-378.
3. Bruno-Joyce J, Dugas JM, MacCausland OE. 2001. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Annals of Pharmacotherapy 35:1016-1019.
4. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H. 2000. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. Journal of Biological Chemistry 275:4507-4512.
5. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. 2001. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Molecular Pharmacology 59:1277-1286.
6. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 10:1093-1095.
7. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. 2004. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. Journal of Pharmacological Sciences 94:297-304.
8. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. 1991. Biotransformation of pravastatin sodium in humans. Drug Metabolism and Disposition 19:740-748.
9. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y. 2002. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. Journal of Pharmacology and Experimental Therapeutics 300:746-753.
10. Hatanaka T. 2000. Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events. Clinical Pharmacokinetics 39:397-412.
11. Hosoyamada M, Obinata M, Suzuki M, Endou H. 1996. Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene. Archives of Toxicology 70:284-292.
12. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H. 2004. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. Journal of Pharmacological Science 94:197-202.
13. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clinical Pharmacology and Therapeutics 73:538-544.
14. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. 2005. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. Journal of Pharmacology and Experimental Therapeutics 314:1059-1067.
15. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. 2004. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceedings of the National Academy of Sciences of the United States of America 101:3569-3574.
16. Nakagawa A, Shigeta A, Iwabuchi H, Horiguchi M, Nakamura K, Takahagi H. 1991. Simultaneous determination of gemfibrozil and its metabolites in plasma and urine by a fully automated high performance liquid chromatographic system. Biomedical Chromatography 5:68-73.
17. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K. 2001. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. Journal of Pharmacology and Experimental Therapeutics 297:861-867.
18. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapeutics 73:554-565.
19. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. 2006. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metabolism and Disposition 34:191-197.
20. Okerholm RA, Keeley FJ, Peterson FE, Glazko AJ. 1976. The metabolism of gemfibrozil. Proceedings of the Royal Society of Medicine 69(suppl. 2):11-14.
21. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. 2002. Mechanistic studies on metabolic interactions between gemfibrozil and statins. Journal of Pharmacology and Experimental Therapeutics 301:1042-1051.
22. Quion JA, Jones PH. 1994. Clinical pharmacokinetics of pravastatin. Clinical Pharmacokinetics 27:94-103.
23. Roca B, Calvo B, Monferrer R. 2002. Severe rhabdomyolysis and cerivastatin - gemfibrozil combination therapy. Annals of Pharmacotherapy 36:730-731.
24. Sekine T, Miyazaki H, Endou H. 2006. Molecular physiology of renal organic anion transporters. Americal Journal of Physiology. Renal Physiology 290:F251-F261.
25. Shitara Y, Sugiyama Y. 2006. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology and Therapeutics 112:71-105.
26. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. Journal of Pharmacology and Experimental Therapeutics 304:610-616.
27. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. Journal of Pharmacology and Experimental Therapeutics 311:228-236.
28. Shitara Y, Sato H, Sugiyama Y. 2005. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 45:689-723.
29. Sun W, Wu RR, Van Poelje PD, Enrion MD. 2001. Isolation of a family of organic anion transporters from human liver and kidney. Biochemical and Biophysical Research Communications 283:417-422.
30. Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, Sugiyama Y. 2005. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharmaceutical Research 22:647-660.
31. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y. 2006. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metabolism and Disposition 34:743-747.
32. Takeda M, Noshiro R, Onozato ML, Tojo A, Hasannejad H, Huang XL, Narikawa S, Endou H. 2004. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. European Journal of Pharmacology 483:133-138.
33. Uwai Y, Saito H, Inui K. 2000. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. European Journal of Pharmacology 409:31-36.